Journal of Mind and Medical Sciences
Volume 3

Issue 1

Article 9

2016

Finasteride adverse effects and post-finasteride syndrome;
implications for dentists
Stana Paunica
Carol Davila University, Faculty of Dental Medicine, Department of Periodontology, spaunica@yahoo.com

Marina Giurgiu
Carol Davila University, Faculty of Dental Medicine, Department of Periodontology

Andrei Vasilache
Carol Davila University, Faculty of Dental Medicine, Department of Periodontology

Ioana Paunica
Carol Davila University, Faculty of General Medicine

Ion Motofei
Carol Davila University, Faculty of General Medicine

See next page for additional authors
Follow this and additional works at: https://scholar.valpo.edu/jmms
Part of the Oral Biology and Oral Pathology Commons, and the Periodontics and Periodontology
Commons

Recommended Citation
Paunica, Stana; Giurgiu, Marina; Vasilache, Andrei; Paunica, Ioana; Motofei, Ion; Vasilache, Adriana;
Dumitriu, Horia Traian; and Dumitriu, Anca Silvia (2016) "Finasteride adverse effects and post-finasteride
syndrome; implications for dentists," Journal of Mind and Medical Sciences: Vol. 3: Iss. 1, Article 9.
Available at: https://scholar.valpo.edu/jmms/vol3/iss1/9

This Research Article is brought to you for free and open access by ValpoScholar. It has been accepted for
inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more
information, please contact a ValpoScholar staff member at scholar@valpo.edu.

Finasteride adverse effects and post-finasteride syndrome; implications for
dentists
Authors
Stana Paunica, Marina Giurgiu, Andrei Vasilache, Ioana Paunica, Ion Motofei, Adriana Vasilache, Horia
Traian Dumitriu, and Anca Silvia Dumitriu

This research article is available in Journal of Mind and Medical Sciences: https://scholar.valpo.edu/jmms/vol3/
iss1/9

J Mind Med Sci. 2016; 3(1): 71-79. Research Article

Finasteride adverse effects and post-finasteride
syndrome; implications for dentists
1

Stana Paunica, 1Marina Giurgiu, 1Andrei Vasilache, 2Ioana Paunica, 2Ion Motofei,
1
Adriana Vasilache, 1Horia Traian Dumitriu, 1Anca Silvia Dumitriu
1

Carol Davila University, Faculty of Dental Medicine, Department of Periodontology, 2Carol Davila University,
Faculty of General Medicine

Abstract

Finasteride is a 5α-reductase inhibitor widely used in present in the therapeutic approach of
androgenic alopecia. Adverse effects consist in variable sign and symptoms, the most common being
represented by mental troubles (reduced feeling of life pleasure or emotions, depression), physical
impairments (loss of muscle tone and/or mass) and sexual complains (loss of libido and sexual
potency). An increasing number of studies identify and describe even a post-finasteride syndrome
(persistent adverse affects three months or more after finasteride cessation) or new adverse effects
including but not limited at the skin level or oral cavity (marginal periodontium).
We intend to present in this study several oral adverse effects encountered during finasteride
administration, represented by mild and moderate signs which generally responded to topical
procedures without to require the stop of the drug administration. New studies on large samples will
further document the existing relation between the described oral adverse effects and the implied
pathophysiological mechanisms. For this moment, we are taking into account as possible
mechanisms- a direct action of finasteride administration, possible indirect consequences due to
hormonal interferences, or coexisting factors with finasteride administration that were not detected.
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Finasteride adverse effects

Introduction

Recent studies show that finasteride side

Finasteride is

a 5α-reductase inhibitor, effects can occur at the level of oral cavity too, in

extensively used in present in the therapeutic the

form

of

various

signs

and

symptoms

approach of male pattern hair loss. It is approved (erythema, purpura, gingival hypertrophy) (6, 7).
only for men with androgenetic alopecia, being not The current study is aimed to present oral
indicated for women or in the case of pediatric finasteride adverse effects encountered on a
patients. Finasteride is also used for benign
prostatic hyperplasia (5mg/ day), being suspected

sample of men taking the drug for androgenic
alopecia.

that could increase the risk of high-grade prostate
cancer. In respect to androgenetic alopecia,
finasteride can be administered in the form of
tablets, 1mg/ day, or as topical solution applied on
the scalp once or twice a day (1-3).
Finasteride

is

extensively

Materials and Methods
The study group taking finasteride was
represented

by

eighty

four

subjects

with

androgenic alopecia, who received the drug 1 mg
degraded

to daily, six month or more. Inclusion criteria used to

inactive metabolites in liver, which are further recruit subjects were as follow: men with
eliminated through urine and bile. As active androgenic alopecia, presenting no significant
compound, finasteride prevents conversion of (mental, sexual, cutaneous, oral) affections prior
testosterone, progesterone and deoxycorticosterone the treatment, and taking no specific diets or drugs
to

the

corresponding

metabolites,

namely for general conditions (obesity, hypertension, etc.).

dihydrotestosterone (DHT), dihydroprogesterone, According to literature data, finasteride proved to
dihydrodeoxycorticosterone. All these mediators be able to induce a lot of adverse effects during
act within the brain modulating not only sexual and after administration. As a consequence, we
receptors but also the action of γ-aminobutyric acid designed and performed the study with several
on

the

corresponding

GABA

receptors. specialists to cover a wider field of study,

Accordingly, the most frequent adverse effects including

dermatologists,

psychiatrists,

induced by finasteride are related to mental psychologists, urologists, and dentists. Subjects
(depression) and sexual (loss of libido and sexual were monitored in respect to adverse effects
potency) symptoms, which are encountered not encountered not only during therapeutic phase but
only during finasteride administration but also also after treatment cessation, for at least four
after treatment cessation (as post-finasteride months.
syndrome) (4, 5).
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(8). It is in part genetically determined, being

Results
On our sample, the most notable adverse
effects encountered during therapeutic phase were
as follow: depression (8,33%), gastrointestinal
disturbances (5,95%), decreased libido (7,14%)
and erectile dysfunction (2,38%). At four months
after finasteride cessation, the “post-finasteride”
syndrome was represented by depression (4,76%),
erectile dysfunction (1,19%) and ejaculation
disorders (2,38%). The subjects included in the
study received no additional treatments after

gingivo-parodontal

lesions

were

encountered during finasteride administration at
21,42% subjects: 6 with mucosal pallor, 5 with
erythema, 3 with purpura, 2 with periodontal
inflammation, and 2 with gingival hypertrophy.
Excepting

the

two

androgens (particularly DHT) that are essential for
the progression of this condition. Frontal skin
contains large amounts of 5 α-reductase, the
androgen-dependent processes from this level
(DHT binding to the specific receptors) leading to
androgenic alopecia. The onset of the affection is
often gradual. Men have thinning hair in the
temporal areas, the shape of the anterior scalp
changing. The disease evolves progressively
towards the frontal area and vertex (9).

finasteride cessation.
The

augmented by specific hormonal factor like

patients

with

gingival

hypertrophy who required discontinuation of
finasteride to be ameliorated (regressing totally in
less than three months after finasteride cessation),
the other oral lesions were treated through specific/

For women it is common a diffuse hair loss,
and usually in a lesser degree than in men (women
generally maintaining a frontal hair line). Women
should not handle finasteride tablets during
pregnancy due to potential risk to a male fetus.
When received the drug for idiopathic hirsutism,
women recorded a hirsutism score that improved
significantly after 6-9 months after the therapy
onset (10).
Pharmacologically, finasteride is a 5 alpha-

local procedures, without to be necessary to stop reductase inhibitor which acts selectively on type
the finasteride administration.

II and III isoenzymes. It is a partial inhibition of
DHT synthesis, due to the fact that finasteride
doesn’t inhibit the type I of 5 alpha-reductase

Discussion

isoenzyme. Consequently, the conversion of

Androgenic alopecia affects nearly 30% of testosterone to dihydrotestosterone is partially
men under 30 years, 50% of men over 50 years and inhibited, serum level of DHT decreasing after
surprisingly, about 40% of women over 50 years finasteride administration with about 65–70% (11).

Finasteride adverse effects

Finasteride adverse effects described in lower/ ignored if the patients would not be advised
literature differ from study to study. Thus, the (18).
genitourinary symptoms seems to be not only
physical but also functional, represented by penile
and scrotal shrinkage and numbness, decreased
semen volume and force, erectile dysfunction,
decreased libido, and decreased or loss of orgasm
(12, 13).

A lot of adverse effects related to finasteride
are encountered not only during Finasteride
administration but also after treatment cessation, in
the form of post-Finasteride syndrome. In other
words, the post-Finasteride syndrome should be
delineated (as a distinct pathophysiological entity)

Mental and neurological troubles consist in by the adverse effects which are encountered
memory impairment, decreased comprehension, during Finasteride administration. Adverse effects
depression, anxiety, suicidal thoughts, insomnia, encountered

during

finasteride

administration

would be the consequences of a direct finasteride

anhedonia and emotional flatness (14, 15).

action, and indirect consequences of subsequent
Physically, finasteride adverse effects are
represented

by

gynecomastia

(female-like

enlargement of the breast), chronic fatigue, muscle
twitching

and

atrophy,

decreased

body

hormonal interferences. After finasteride cessation,
adverse effects should be assigned only to the
residual hormonal interferences, represented by
altered level of certain neuroactive steroids in

temperature, increased fat deposition/ elevated cerebrospinal fluid and plasma. In support of this
body mass index, cardiovascular impairments delineation between finasteride and post(palpitations, hypotension), dermatologic and oral finasteride adverse effects, recent studies show that
manifestations (chronically dry, pruritus, rash, the frequency of finasteride side effects (occurring
urticaria, erythema, purpura, gingival hypertrophy) during Finasteride administration) is greater in
(16, 17).
It seems that the nature and frequency of the
above described adverse effects depend not only
by the study design but also by the sample studied.

right handed men, while the post-finasteride
syndrome is encountered with a similar frequency
in right and left handed men (7, 12, 19).
A lot of general conditions have (in different

Just an example, it was found that the frequency of developmental stages) significant effects at the
finasteride side effects would be significantly level of oral cavity. The most notable diseases are
higher when the patients are informed (before represented by: chronic hepatitis, chronic renal
treatment) about the possible adverse effects, and diseases,

chronic

heart

failure,

venous
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insufficiency,

malignant

tumors,

nutritional hypertrophy (who required discontinuation of

diseases and diabetes, immunologic diseases, etc finasteride administration), all oral lesions were
(20, 21).

treated through specific/ local procedures, without

In addition, there are described more than a
hundred drugs which may cause side effects to the
oral mucosa/ marginal periodontium when are
administered in the curative or symptomatic
treatment of previously mentioned affections.

to be necessary to stop the drug administration. No
oral lesions were identified on our sample at three
months after finasteride cessation (as possible
signs

and/or

symptoms

of

post-finasteride

syndrome).

Pharmacological classes including drugs with oral

Finasteride and levamisole decrease the

side effects are represented by: antidepressants, conversion of testosterone to DHT; in addition,
antipsychotics,

antihistamines,

diuretics, these drugs inhibit alkaline phosphatase, an

antihypertensives, muscarinic antagonists, anti- enzyme that stimulates the synthesis of DHT (23).
inflammatories, bronchodilators, muscle relaxants, Conversion of testosterone to DHT is increased in
antimigraine drugs, opioids, benzodiazepines and gingival inflammation. Yet, DHT is considered to
hypnotics,

H2

antagonists

and

proton-pump be an important stimulator of fibroblast activity

inhibitors, cytotoxic medications, retinoids, anti- (24). Starting from these findings, some authors
HIV medication and cytokines (alpha interferon) . suggested that finasteride can be used in the form
Clinical manifestations dependent by: drug type, of topical application (in a suitable vehicle) to
dose, the degree of cumulative toxicity, patient partially block the proliferation of fibroblast
particularities, etc. These reactions can occur hyperplasia following phenytoin administration
immediately, or after days, weeks or months from (23).
administration onset (22).

Testosterone-specific receptors have been

In respect to adverse effects from oral cavity isolated from periodontal tissue levels (25). The
we found on our sample (consisting in eighty four number of receptors in the gingival fibroblasts
subjects) that the finasteride adverse effects were tends to increase inflammation or gingival
encountered only during finasteride administration, hyperplasia (26). At the gingival level, testosterone
being represented by mucosal pallor (6 patients), stimulates the matrix synthesis via osteoblasts and
erythema (5 patients), purpura (3 patients), fibroblasts from periodontal ligament (26- 29),
periodontal inflammation (2 patients) and gingival stimulates the proliferation and differentiation of
hypertrophy (2 patients). Excepting gingival osteoblasts (30), reduce the production of IL-6

Finasteride adverse effects

during

inflammation

through

inhibition

of

In respect to our results, finasteride adverse

prostaglandin (31- 33), increase the concentration effects encountered to oral cavity were mild to
of osteoprotegerin (34).

moderate, and generally responded to topical

As a conclusion, finasteride adverse effects
encountered on our sample at the level of marginal
periodontium could be the consequences of a direct
finasteride

action,

consequences

of

and

possible

subsequent

indirect
androgenic

procedures without to require the stop of the drug
administration. New studies on large samples will
further document the existing relation between the
described oral adverse effects and the implied
pathophysiological

mechanisms

(direct

consequence of finasteride administration, indirect

interferences.

consequences due to hormonal interferences, or no
relation to finasteride). Yet, new studies should
Conclusions

investigate if the subgroup of persons susceptible

Male androgenic alopecia is perceived by to develop finasteride adverse effects could be
some men as a stressful condition, many affected identified prior to finasteride administration, using
persons resorting usually to specialized assistance individual predictive factors (36).
(from

family

treatment/

physician,

amelioration.

dermatologists)
The

most

for

common
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